B of A Securities analyst Greg Harrison downgrades Beam Therapeutics (NASDAQ:BEAM) from Buy to Neutral and announces $35 price target.
B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.